Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)
China
· Delayed Price · Currency is CNY 5.93
-0.06 (-1.00%)
May 14, 2025, 9:45 AM CST
SHE:002550 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,514 | 1,524 | 1,809 | 2,302 | 1,874 | 1,667 | Upgrade
|
| Other Revenue | 2.39 | 2.39 | 5.17 | 1.13 | 1.02 | 0.54 | Upgrade
|
| Revenue | 1,516 | 1,526 | 1,814 | 2,304 | 1,875 | 1,668 | Upgrade
|
| Revenue Growth (YoY) | -9.06% | -15.88% | -21.24% | 22.86% | 12.43% | -0.45% | Upgrade
|
| Cost of Revenue | 685.86 | 696.31 | 1,045 | 1,419 | 1,045 | 880.42 | Upgrade
|
| Gross Profit | 830.16 | 829.94 | 768.81 | 884.31 | 829.44 | 787.19 | Upgrade
|
| Selling, General & Admin | 419.4 | 423.58 | 521.42 | 541.03 | 587.29 | 483.04 | Upgrade
|
| Research & Development | 103.36 | 104.45 | 97.08 | 88.31 | 71.18 | 69.14 | Upgrade
|
| Other Operating Expenses | 9.73 | 13.75 | 7.13 | 17.1 | 18.35 | 19.96 | Upgrade
|
| Operating Expenses | 538.54 | 547.81 | 606.62 | 661.74 | 677.06 | 577.18 | Upgrade
|
| Operating Income | 291.63 | 282.12 | 162.19 | 222.56 | 152.38 | 210.01 | Upgrade
|
| Interest Expense | -1.39 | -1.39 | -5.93 | -5.23 | -1.66 | -8.44 | Upgrade
|
| Interest & Investment Income | 20.81 | 21.49 | 19.3 | 5.64 | 1.6 | 21.61 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.73 | 3.73 | 1.26 | 74.02 | -5.4 | -17.71 | Upgrade
|
| Other Non Operating Income (Expenses) | 145.11 | 84.85 | -1.83 | -0.02 | 52.55 | -378.37 | Upgrade
|
| EBT Excluding Unusual Items | 459.89 | 390.8 | 175 | 296.97 | 199.48 | -172.91 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.47 | 2.36 | 0.77 | -4.59 | 0.64 | 0.44 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 25.35 | 57.59 | - | - | Upgrade
|
| Asset Writedown | -0.04 | -0.04 | -7.77 | -0.24 | -0.46 | -1.6 | Upgrade
|
| Other Unusual Items | 2.72 | 2.72 | 10.18 | 10.6 | 9.72 | 4.95 | Upgrade
|
| Pretax Income | 466.04 | 395.84 | 203.52 | 360.33 | 209.38 | -169.12 | Upgrade
|
| Income Tax Expense | 76.59 | 62.66 | 24.85 | 40.42 | 23.04 | -21.49 | Upgrade
|
| Earnings From Continuing Operations | 389.45 | 333.18 | 178.67 | 319.91 | 186.34 | -147.63 | Upgrade
|
| Minority Interest in Earnings | 23.45 | 22.85 | 3.19 | 3.5 | -5.26 | 15.61 | Upgrade
|
| Net Income | 412.89 | 356.03 | 181.86 | 323.41 | 181.08 | -132.02 | Upgrade
|
| Net Income to Common | 412.89 | 356.03 | 181.86 | 323.41 | 181.08 | -132.02 | Upgrade
|
| Net Income Growth | 106.42% | 95.77% | -43.77% | 78.60% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 1,269 | 1,272 | 1,299 | 1,294 | 1,207 | 1,200 | Upgrade
|
| Shares Outstanding (Diluted) | 1,269 | 1,272 | 1,299 | 1,294 | 1,207 | 1,200 | Upgrade
|
| Shares Change (YoY) | -1.91% | -2.11% | 0.41% | 7.16% | 0.58% | -4.01% | Upgrade
|
| EPS (Basic) | 0.33 | 0.28 | 0.14 | 0.25 | 0.15 | -0.11 | Upgrade
|
| EPS (Diluted) | 0.33 | 0.28 | 0.14 | 0.25 | 0.15 | -0.11 | Upgrade
|
| EPS Growth | 110.44% | 100.00% | -44.00% | 66.67% | - | - | Upgrade
|
| Free Cash Flow | 311.39 | 424.07 | 433 | -142.46 | 13.19 | 254.74 | Upgrade
|
| Free Cash Flow Per Share | 0.24 | 0.33 | 0.33 | -0.11 | 0.01 | 0.21 | Upgrade
|
| Dividend Per Share | 0.120 | 0.120 | 0.120 | 0.120 | 0.120 | 0.120 | Upgrade
|
| Dividend Growth | - | - | - | - | - | -52.00% | Upgrade
|
| Gross Margin | 54.76% | 54.38% | 42.38% | 38.39% | 44.24% | 47.21% | Upgrade
|
| Operating Margin | 19.24% | 18.48% | 8.94% | 9.66% | 8.13% | 12.59% | Upgrade
|
| Profit Margin | 27.23% | 23.33% | 10.02% | 14.04% | 9.66% | -7.92% | Upgrade
|
| Free Cash Flow Margin | 20.54% | 27.79% | 23.87% | -6.18% | 0.70% | 15.28% | Upgrade
|
| EBITDA | 355.08 | 346.73 | 231.41 | 287.33 | 221.82 | 280.26 | Upgrade
|
| EBITDA Margin | 23.42% | 22.72% | 12.75% | 12.47% | 11.83% | 16.81% | Upgrade
|
| D&A For EBITDA | 63.46 | 64.61 | 69.22 | 64.76 | 69.43 | 70.25 | Upgrade
|
| EBIT | 291.63 | 282.12 | 162.19 | 222.56 | 152.38 | 210.01 | Upgrade
|
| EBIT Margin | 19.24% | 18.48% | 8.94% | 9.66% | 8.13% | 12.59% | Upgrade
|
| Effective Tax Rate | 16.43% | 15.83% | 12.21% | 11.22% | 11.00% | - | Upgrade
|
| Revenue as Reported | 1,526 | 1,526 | 1,814 | 2,304 | 1,875 | 1,668 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.